The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Pierre FenauxDuring the 2021 ASCO Annual Meeting, the MDS Hub spoke with Pierre Fenaux, Hôpital Saint-Louis, Paris, FR. We asked, Which subgroups of patients benefit most from a Venetoclax+Azacitidine (Ven+Aza) combination?
Which subgroups of patients benefit most from a Ven+Aza combination?
Fenaux explains the current use for Ven+Aza before outlining early efficacy data from trials investigating this combination for high-risk MDS, highlighting the effect on earlier response rates and preventing later myelosuppression. He then suggests further stratification of this subgroup, including karyotype and transplant eligibility. Finally, he proposes the possibility for new combination therapies to improve survival in MDS.